ARGOS - A phase IV, prospective, 18-month study to assess the effectiveness and safety of bimatoprost intracameral implant (DURYSTA) in US clinical practice

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2021 - November 1, 2022